Lupus & antiphospholipid syndrome
Clinical features and two-year outcomes in systemic lupus erythematosus patients with heart failure and reduced, mid-range and preserved ejection fractions
Authors' conclusion
SLE patients with HF tend to have an early disease onset, high SLE activity and long course, with HFpEF being the predominant phenotype. HFrEF has a poorer prognosis compared to HFpEF, while HFmrEF has an intermediate prognosis and shares more clinical similarities with HFrEF.
Study context
- Population
- Patients with SLE and HF hospitalized in Jinling Hospital, January 2013 to May 2021
- Participants
- 376 patients
- Exposure
- HFrEF vs HFmrEF vs HFpEF in SLE patients with HF
- Outcome
- Death and ESKD (overall and renal survival)
- Follow-up
- 2 years
Methodological detailssingle-centre, 2-year follow-up after discharge, multivariate Cox analysis
- Single-centre
- 2-year follow-up after discharge
- Multivariate Cox analysis
Main finding
As reported in the abstract
Overall survival
- 2-year overall survival, all patients
- 86.97%
Observational data: associations, not effects.
Further findings
Renal survival · 2 years
HF phenotype distribution
- Renal survival — 2-year renal survival, all patients
- 63.56%
Risk factors (multivariate Cox)
- Death: age, NPSLE, blood NT-proBNP, CD20+ B cells, Alb, UA
- ESKD: Scr, PCT, CD20+ B cells, urine RBP, right kidney size
SLE remission or relapse among non-ESKD survivors
- No significant differences among the three groups
Original publication
Clinical features and two-year outcomes in systemic lupus erythematosus patients with heart failure and reduced, mid-range and preserved ejection fractions. Lupus. Published 10 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →